EZH2 is a critical methyltransferase catalysing H3K27 and exhibits inappropriate expression in various aggressive cancers including thyroid carcinoma.26, 27 Tazemetostat, a novel EZH2 inhibitor, has showed a favourable antitumour activity and represented a potential agent for sorafenib‐resistant thyroid carcinoma.28, 29. This evidence concerns the gene EZH2 and thyroid gland carcinoma.